INVESTOR RESOURCES
iCHOR COMPANY INFORMATION, NEWS & PRESENTATIONS
Corporate Overview
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair who saw an opportunity to develop new technologies to address the large unmet needs in treating peripheral vascular occlusions. They have devised a technology that has converted the tried and proven Fogarty balloon sweep method from an open surgery to a minimally-invasive endovascular procedure. The overall corporate objective is to focus on creating a one-size-fits-all system that replicates successful parameters of surgical clot removal while addressing the shortcomings of current therapeutic options. The Team’s long-term vision is for the iSWEEP system to become the standard of care and first-line therapy for treating peripheral vascular occlusions, increasing clinical flexibility while delivering improved outcomes at a lower cost. The iCHOR team consists of a group of experienced multi-disciplinary members, including entrepreneurs, executives, physicians, regulatory experts, and engineers. Together, we bring a broad range of experience in the development, regulatory approval, and commercialization of medical devices in the peripheral vascular space.
iCHOR at LSI '24
Medline Review Articles
The Latest News
A No Compromise Approach to Peripheral Thrombectomy
Innovative new technologies like iSWEEP, embodied in iART and iDVT, clearly demonstrate that peripheral thrombectomy does not have to compromise. No longer do practitioners need to live with the inherent shortcomings of existing aspiration systems, metal draggers, or lytic therapy approaches. Using a proven mechanism of action that mirrors the 60 year surgical Fogarty experience long proven to be effective…
The Memo: iCHOR Vascular Simply Taking a Proven Surgical Fogarty Sweep Into the Endovascular Labs
Under the leadership of Co-Founder and CEO Tim Blair, ICHOR Vascular Inc. is advancing a new approach to treating peripheral vascular occlusions by converting one of surgery’s most proven techniques into a simple, minimally invasive endovascular procedure. Founded to address shortcomings in clot removal, the company’s iSWEEP platform modernizes the classic Fogarty balloon sweep, delivering rapid vessel clearance without thrombolytic…